These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 31387689)
1. RF-New Recombinant Vaccine for the Prevention of Herpes Zoster. Morgado-Carrasco D; Fustà-Novell X; Giavedoni P Actas Dermosifiliogr (Engl Ed); 2020 Jan; 111(1):67-68. PubMed ID: 31387689 [No Abstract] [Full Text] [Related]
2. Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. Anderson TC; Masters NB; Guo A; Shepersky L; Leidner AJ; Lee GM; Kotton CN; Dooling KL MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(3):80-84. PubMed ID: 35051134 [TBL] [Abstract][Full Text] [Related]
3. Zoster vaccine to prevent postherpetic neuralgia. Sederholm B; Peterson D J Pain Palliat Care Pharmacother; 2006; 20(4):41-2. PubMed ID: 17182505 [TBL] [Abstract][Full Text] [Related]
4. [Pain in herpes zoster: Prevention and treatment]. Calvo-Mosquera G; González-Cal A; Calvo-Rodríguez D; Primucci CY; Plamenov-Dipchikov P Semergen; 2017; 43(4):318-327. PubMed ID: 27053513 [TBL] [Abstract][Full Text] [Related]
5. Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines. Dooling KL; Guo A; Patel M; Lee GM; Moore K; Belongia EA; Harpaz R MMWR Morb Mortal Wkly Rep; 2018 Jan; 67(3):103-108. PubMed ID: 29370152 [TBL] [Abstract][Full Text] [Related]
10. [Vaccination against herpes-zoster: a new strategy for post-herpetic neuralgia]. Gil de Miguel A An R Acad Nac Med (Madr); 2009; 126(1):57-66; discussion 67-72. PubMed ID: 20432659 [TBL] [Abstract][Full Text] [Related]
11. Recombinant Zoster Vaccine (Shingrix): Real-World Effectiveness in the First 2 Years Post-Licensure. Izurieta HS; Wu X; Forshee R; Lu Y; Sung HM; Agger PE; Chillarige Y; Link-Gelles R; Lufkin B; Wernecke M; MaCurdy TE; Kelman J; Dooling K Clin Infect Dis; 2021 Sep; 73(6):941-948. PubMed ID: 33580242 [TBL] [Abstract][Full Text] [Related]
12. Update on herpes zoster vaccine: licensure for persons aged 50 through 59 years. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2011 Nov; 60(44):1528. PubMed ID: 22071592 [TBL] [Abstract][Full Text] [Related]
14. Early examination of real-world uptake and second-dose completion of recombinant zoster vaccine in the United States from October 2017 to September 2019. Patterson BJ; Chen CC; McGuiness CB; Glasser LI; Sun K; Buck PO Hum Vaccin Immunother; 2021 Aug; 17(8):2482-2487. PubMed ID: 33849373 [No Abstract] [Full Text] [Related]
15. Insurance reimbursements for recombinant zoster vaccine in the private sector. Leidner AJ; Tang Z; Guo A; Anderson TC; Tsai Y Vaccine; 2021 Aug; 39(36):5091-5094. PubMed ID: 34348844 [TBL] [Abstract][Full Text] [Related]
16. Shingrix for Herpes Zoster: A Review. Shah RA; Limmer AL; Nwannunu CE; Patel RR; Mui UN; Tyring SK Skin Therapy Lett; 2019 Jul; 24(4):5-7. PubMed ID: 31339679 [TBL] [Abstract][Full Text] [Related]
17. More advances for dermatology patients. Hill MJ Dermatol Nurs; 2006 Dec; 18(6):529. PubMed ID: 17286153 [No Abstract] [Full Text] [Related]
18. Vaccination for quality of life: herpes-zoster vaccines. Lang PO; Aspinall R Aging Clin Exp Res; 2021 Apr; 33(4):1113-1122. PubMed ID: 31643072 [TBL] [Abstract][Full Text] [Related]
19. FDA expands age range for shingles vaccine. Voelker R JAMA; 2011 Apr; 305(15):1526. PubMed ID: 21505126 [No Abstract] [Full Text] [Related]